Allergan's add-on treatment for depression fails late-stage studies

Allergan's add-on treatment for depression fails late-stage studies

Allergan Plc said on Wednesday its experimental add-on treatment for major depressive disorder failed to meet the main goals of three late-stage studies.

FILE PHOTO: The Allergan logo is seen in this photo illustration
FILE PHOTO: The Allergan logo is seen in this photo illustration November 23, 2015. To match special report USA-FDA/CASES REUTERS/Thomas White/Illustration/File Photo

REUTERS: Allergan Plc said on Wednesday its experimental add-on treatment for major depressive disorder failed to meet the main goals of three late-stage studies.

The trials evaluated the efficacy, safety and tolerability of Allergan's treatment, rapastinel, compared to a placebo, both in combination with antidepressant therapy (ADT) in patients with depression who had a partial response to ADT, the company said.

(Reporting by Manogna Maddipatla in Bengaluru; Editing by Sriraj Kalluvila)

Source: Reuters

Bookmark